Search our Innovation Portfolio

With Roche Diagnostics Ltd, this 18-month project will explore the use of an innovative solution, called Elecsys®GAAD, to improve early Hepatocellular Carcinoma (HCC) detection. Elecsys®GAAD is a fully regulated, accurate test that combines blood tests with gender and age. If raised, it can suggest the presence of HCC. It will be used alongside routine surveillance tests to see if it can help in finding HCC earlier so patients have the best chance of surviving this cancer.

The University of Manchester and NIHR Manchester Biomedical Research Centre.

Using population level data to model lung cancer risk in Hodgkin lymphoma survivors, researchers at The NIHR Manchester Biomedical Research Centre, The University of Manchester and University of Oxford developed extended criteria and a modified risk calculator to identify Hodgkin lymphoma survivors at increased risk of developing lung cancer as a late complication of previous cancer treatment.

The SEARCH project funded by SBRI Healthcare will implement and evaluate this technology for identification and screening of high risk Hodgkin lymphoma survivors within the NHS Lung Cancer Screening Programme. Results will generate evidence to support routine adoption.

There is intense pressure on global health care systems, in the UK this has resulted in a challenge to the NHS to deliver £20 bn of efficiency savings by 2020. Our sister company Xytal have unique experience of increasing productivity in the English primary care sector, by utilising lean process improvement techniques. This has revealed that there are some standardised protocol driven processes that could be cheaper and more reliably performed by automated machine based information systems.It is Xytek’s intention to develop, test and roll out heuristic clinical support software to relieve the clinician of repetitive rules based tasks.